Business
Hoth Therapeutics, Inc. Announces Positive Results from Pilot Study of BioLexa on Diabetic Skin Ulcers
NEW YORK, July 22, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, July 22, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initial results of its Pilot Study of the BioLexa Platform's application on diabetic skin ulcers. \nThis pilot study was designed to establish foundational protocols for assessing effectiveness of a therapeutic compound developed by Hoth Therapeutics, the BioLexa Platform, for accelerating and improving wound healing in the context of acute and chronic diabetic ulcers, using an animal model of impaired wound healing developed at Massachusetts General Hospital (MGH).\nSpecific study objectives were: \nOptimize the method of application of the therapeutic compound (BioLexa) on diabetic skin wounds in the mouse models of acute and chronic diabetic wound healing established at the Vaccine and Immunotherapy Center (VIC) at MGH directed by Dr. Mark Poznansky. Optimize the Staphylococcus aureus inoculation dose to achieve biofilm growth in the infected diabetic wound model. An animal protocol amendment was submitted to and approved by the MGH Institutional Animal Care and Use Committee (IACUC) to allow the application of the BioLexa compound on wounds in the established mouse model \nA full Biosafety protocol was submitted to and approved by the Partners Institutional Biosafety Committee (IBC) to allow the use of pathogens such as S. aureus. \nAll work was performed in compliance with these institutionally approved protocols. \nAfter 22 days post-injury, the animals were euthanized and the dressings on the wounds were removed to reveal the wounds and collect tissue biopsies. \nUpon removal of the wound dressings and the obscuring cream, Dr. Ruxandra Sirbulescu, who designed and conducted the pilot study at MGH, observed that the majority of the wounds, treated with either BioLexa or the carrier base control of BioLexa, were fully closed and re-epithelialized. While the present pilot study did not include wounds treated with saline solution, previous studies in this model have shown that wounds treated with control solutions, such as saline, remain fully open ulcers at 22 days post injury (Sirbulescu et al., 2017, Wound...